• 1
    Provan D, Stasi R, Newland AC et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:16885.
  • 2
    British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and pregnancy. Br J Haematol 2003; 120:57496.
  • 3
    Jorquera JI. Flebogamma® 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy. Clin Exp Immunol 2009; 157 (Suppl. 1):1721.
  • 4
    Lim W. Antiphospholipid antibody syndrome. Hematol Am Soc Hematol Educ Program 2009: 2339.
  • 5
    Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005; 106:224451.
  • 6
    Berger M, Flebogamma 5% DIF investigators. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency disease (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. J Clin Immunol 2007; 27:62833.